Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Pharming Group N.V.NASDAQ: PHAR

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns positive

Q1 FY2026 other income / expenses was $535K, compared with -$4.74M a year earlier. Trailing-twelve-month other income / expenses was -$3.5M.

Context

  • Other income / expenses amounted to 2.1% of revenue in FY2025, up 2.1 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near $535K or moves back toward the trailing-twelve-month quarterly average of -$875.52K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$535K-80.9% QoQ
Last fiscal yearDec 2025
-$8.03M-6114.5% YoY
LTMMar 2026
-$3.5M+18.6% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+111.3%——
1 year-6114.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(8.03M) USD
Year-over-year change
-6114.5%

Other Income / Expenses vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +18.6% is the 4th highest of 9, against a peer median of +9.3%.
  • Other income / expenses amounts to 0.9% of revenue for PHAR, versus a peer median of 7.2%.
PHAR Competitors
Other Income / Expenses for PHAR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$26.12M USD+72.4%—39.5%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$21.61M USD+11.8%-76.4%2.3%
PHVSPharvaris N.V.LTM Sep 2026€14.39M EUR+118.3%——
STOKStoke Therapeutics, Inc.LTM Mar 2026$14.2M USD+6.7%+60.9%44.3%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$6.49M USD-46.8%+29.6%—
SLNSilence Therapeutics plcLTM Mar 2026$1.43M USD—-50.1%155.2%
PRQRProQR Therapeutics N.V.LTM Mar 2026€840.44K EUR-70.3%+16.3%6.3%
PHARPharming Group N.V.LTM Mar 2026-$3.5M USD+18.6%—0.9%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026-$68.03M USD+21.3%—7.2%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$49.83B USD-78235.6%—4.9%
Peer median (excluding PHAR) —+9.3%+16.3%7.2%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue225.46M205.62M245.32M307.75M377.18M
Cost of Revenue23.97M17.56M25.21M36.66M45.63M
Gross Profit201.49M188.06M220.1M271.09M331.56M
Gross Margin89.4%91.5%89.7%88.1%87.9%
Research & Development79.78M52.53M68.91M86.1M98.08M
Selling, General & Admin54.56M68.85M87.5M102.74M117.44M
Operating Expenses186.12M169.83M225.49M280.02M309.75M
Depreciation & Amortization22.23M13.19M15.93M16.64M10.76M
EBITDA55.3M33.53M9.88M16.89M31.7M
EBITDA Margin24.5%16.3%4.0%5.5%8.4%
Operating Income15.37M18.23M(5.39M)(8.93M)20.88M
Operating Margin6.8%8.9%-2.2%-2.9%5.5%
Interest Income59.99K85K3.53M5.92M2.56M
Interest Expense7M5.36M5.96M9.05M21.31M
Other Income / Expenses10.79M(3.25M)(6.63M)133.58K(8.03M)
Income Before Tax26.16M14.99M(12.01M)(8.79M)12.88M
Pre-Tax Margin11.6%7.3%-4.9%-2.9%3.4%
Income Tax Expense8.03M1.31M(1.46M)3.47M10.34M
Net Income18.13M13.67M(10.55M)(12.26M)2.86M
Net Margin8.0%6.7%-4.3%-4.0%0.8%
EPS (Basic)0.230.17(0.14)(0.18)0.04
EPS (Diluted)0.210.16(0.14)(0.18)0.04
Weighted Avg Shares87.64M82.54M65.7M68.92M71.32M
Weighted Avg Shares (Diluted)87.64M84.28M65.7M68.92M71.32M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.